|
10375
|
OMB157
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
RNA based vaccine
|
Phase 4
|
Novartis
|
2021
|
Germany
|
18 years and above
|
NA
|
Subcutaneous
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
Ofatumumab
|
NA
|
NCT04869358
|
https://clinicaltrials.gov/show/NCT04869358
|
https://www.ema.europa.eu/en/documents/assessment-report/kesimpta-epar-public-assessment-report_en.pdf
|
|
10376
|
Covishield
|
COVID-19
|
Respiratory
|
SARS-CoV-2 virus
|
positive-sense, single-stranded RNA
|
Non-replicating viral vector
|
Phase 4
|
AstraZeneca plc, University of Oxford, Serum Institute of India
|
2020
|
UK
|
18 years and above
|
2 doses 4 to 12 weeks apart
|
Intramuscular
|
NA
|
Spike protein of SARS-CoV-2 virus
|
ChAdOx1 technology
|
NA
|
University of Oxford
|
Japan, Korea, India
|
AZD1222,ChAdOx1 nCoV-19, ChAdOx1-S, COVID-19 Vaccine AstraZeneca, AstraZeneca COVID-19 Vaccine, AZD2816,Vaxzevria
|
NA
|
NA
|
https://vk.ovg.ox.ac.uk/vk/covid-19-vaccines
|
NA
|
|
10377
|
Lamb rotavirus
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Phase 4
|
Lanzhou Biologicals
|
2000
|
China
|
6 months - 35 months
|
NA
|
Oral
|
NA
|
Single strain of rotavirus found in lamb (G10P)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1
|
https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf
|
|
10378
|
ROTAVIN-M1
|
Rotavirus Infection
|
Gastrointestinal
|
Rotavirus
|
double stranded RNA
|
Live-attenuated
|
Phase 4
|
Polyvac, Center for Research and Production of Vaccines
|
NA
|
Vietnam
|
6 months - 8 months
|
NA
|
Oral
|
NA
|
Human rotavirus strain (G1P)
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
https://www.who.int/immunization/research/meetings_workshops/11_Cassels_Rotavirus_PDVAC_2019.pdf?ua=1
|
https://preventrotavirus.org/wp-content/uploads/2019/05/ROTA-Brief2-ProductLandscape-SP-1-3.pdf
|